Castle Biosciences (CSTL) News Today $18.67 +0.23 (+1.25%) As of 03:15 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CSTL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International ConventionJune 11 at 7:00 AM | globenewswire.comSquarepoint Ops LLC Lowers Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Squarepoint Ops LLC trimmed its position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 51.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,317 shares of the company's stock after sellJune 5, 2025 | marketbeat.comCastle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®June 4, 2025 | finance.yahoo.comShort Interest in Castle Biosciences, Inc. (NASDAQ:CSTL) Drops By 17.2%Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) was the target of a large decline in short interest in May. As of May 15th, there was short interest totalling 1,250,000 shares, a decline of 17.2% from the April 30th total of 1,510,000 shares. Based on an average trading volume of 461,300 shares, the days-to-cover ratio is currently 2.7 days. Currently, 4.8% of the company's stock are sold short.June 4, 2025 | marketbeat.comCastle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®June 4, 2025 | globenewswire.comMackenzie Financial Corp Takes $560,000 Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Mackenzie Financial Corp bought a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 21,020 shares of the company's stock, valued at approximately $560,000. MackenJune 3, 2025 | marketbeat.comWellington Management Group LLP Invests $19.24 Million in Castle Biosciences, Inc. (NASDAQ:CSTL)Wellington Management Group LLP acquired a new position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 722,120 shares of the company'sJune 1, 2025 | marketbeat.comCastle Biosciences, Inc. (CSTL) Unveils Largest Real-World Melanoma Risk Study at ASCO 2025May 30, 2025 | msn.comNew Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival OutcomesMay 29, 2025 | globenewswire.comNuveen Asset Management LLC Has $12.41 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Nuveen Asset Management LLC trimmed its position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 14.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 465,526 shares of the company's stock after sellingMay 28, 2025 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Rating of "Buy" by BrokeragesShares of Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) have been assigned an average recommendation of "Buy" from the eight analysts that are currently covering the firm, MarketBeat.com reports. Eight analysts have rated the stock with a buy rating. The average 1 year price objective aMay 28, 2025 | marketbeat.comBank of America Corp DE Raises Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Bank of America Corp DE increased its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 100.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 403,553 shares of the company'sMay 26, 2025 | marketbeat.comCastle Biosciences amends charter, stockholders voteMay 25, 2025 | investing.comMillennium Management LLC Has $14.63 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Millennium Management LLC increased its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 290.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 548,809 shares of the company's stock after buying anMay 25, 2025 | marketbeat.com90,563 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Purchased by D. E. Shaw & Co. Inc.D. E. Shaw & Co. Inc. bought a new position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 90,563 shares of the company's stock, valued at appMay 23, 2025 | marketbeat.comAmeriprise Financial Inc. Has $8.42 Million Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Ameriprise Financial Inc. trimmed its position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 9.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 316,036 shares of the company's stock after selling 33,May 23, 2025 | marketbeat.comSoleus Capital Management L.P. Has $6.74 Million Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Soleus Capital Management L.P. decreased its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 61.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 252,917 shares of the company's sMay 21, 2025 | marketbeat.comCastle Biosciences to Present at the 2025 Jefferies Global Healthcare ConferenceMay 21, 2025 | globenewswire.comJane Street Group LLC Reduces Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Jane Street Group LLC lessened its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 59.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 59,383 shares of the company's stock after selliMay 21, 2025 | marketbeat.comNorthern Trust Corp Boosts Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Northern Trust Corp boosted its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 8.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 284,587 shares of the company's stock after buying an additionalMay 21, 2025 | marketbeat.comPoint72 Asset Management L.P. Grows Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Point72 Asset Management L.P. lifted its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 9.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 547,104 shares of the company's stock after buying aMay 20, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Has $3.59 Million Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Jacobs Levy Equity Management Inc. trimmed its position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 72.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 134,782 shares of the company's sMay 17, 2025 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Shares Bought by Graham Capital Management L.P.Graham Capital Management L.P. increased its stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 165.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 41,676 shares of the company's stock after buying an addMay 16, 2025 | marketbeat.comBNP Paribas Financial Markets Purchases New Position in Castle Biosciences, Inc. (NASDAQ:CSTL)BNP Paribas Financial Markets purchased a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 249,128 shares of the company's stock, valued at approximately $6,639,000. BNP PariMay 15, 2025 | marketbeat.comGranahan Investment Management LLC Sells 314,396 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)Granahan Investment Management LLC reduced its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 73.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 110,824 shares of the company's stock after sellingMay 13, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Sells 40,700 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)Schonfeld Strategic Advisors LLC decreased its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 72.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,300 shares of the company's stock after selling 40,700 sharesMay 13, 2025 | marketbeat.comCaptrust Financial Advisors Has $5.74 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Captrust Financial Advisors raised its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 2,567.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 215,322 shares of the company's sMay 11, 2025 | marketbeat.comLeerink Partnrs Issues Negative Forecast for CSTL EarningsCastle Biosciences, Inc. (NASDAQ:CSTL - Free Report) - Investment analysts at Leerink Partnrs lowered their Q2 2025 EPS estimates for shares of Castle Biosciences in a research note issued on Monday, May 5th. Leerink Partnrs analyst P. Souda now expects that the company will post earnings of ($0.May 10, 2025 | marketbeat.comReal-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class ResultMay 9, 2025 | globenewswire.comAlgert Global LLC Increases Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Algert Global LLC lifted its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 11.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 149,491 shares of the company's stock after acquiring an additional 15,170 shares during theMay 9, 2025 | marketbeat.comDimensional Fund Advisors LP Increases Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Dimensional Fund Advisors LP raised its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 15.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 999,466 shares of the company's stock after buying an additional 134,645 shareMay 9, 2025 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Price Target Lowered to $37.00 at Canaccord Genuity GroupCanaccord Genuity Group dropped their target price on Castle Biosciences from $42.00 to $37.00 and set a "buy" rating on the stock in a research report on Tuesday.May 8, 2025 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Posts Earnings Results, Misses Expectations By $0.12 EPSCastle Biosciences (NASDAQ:CSTL - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.12). Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%.May 7, 2025 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Q1 2025 Earnings Call TranscriptMay 7, 2025 | msn.comCastle Biosciences Celebrates Skin Cancer Awareness MonthMay 7, 2025 | globenewswire.comTudor Investment Corp ET AL Boosts Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Tudor Investment Corp ET AL lifted its stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 41.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 70,076 shares of the company's stock after purchasiMay 7, 2025 | marketbeat.comCastle Biosciences, Inc.: Castle Biosciences to Acquire PreviseMay 6, 2025 | finanznachrichten.deBellevue Group AG Has $19.88 Million Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Bellevue Group AG lowered its stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 40.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 745,982 shares of the company's stock after sellingMay 6, 2025 | marketbeat.comCastle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call TranscriptMay 5, 2025 | seekingalpha.comCastle Biosciences Reports First Quarter 2025 ResultsMay 5, 2025 | globenewswire.comCastle Biosciences to Acquire PreviseMay 5, 2025 | globenewswire.comCastle Biosciences to Present New TissueCypher Test Data at Digestive Disease Week 2025, Highlighting Risk Stratification for Barrett's EsophagusMay 4, 2025 | nasdaq.comAquatic Capital Management LLC Takes $539,000 Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Aquatic Capital Management LLC purchased a new stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 20,218 shares of the company's stock, valued at aMay 4, 2025 | marketbeat.comNew Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal CancerMay 2, 2025 | globenewswire.comNebula Research & Development LLC Makes New Investment in Castle Biosciences, Inc. (NASDAQ:CSTL)Nebula Research & Development LLC bought a new position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 26,674 shares of the company's stock,May 1, 2025 | marketbeat.comNew Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node PositivityApril 30, 2025 | globenewswire.comJump Financial LLC Cuts Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Jump Financial LLC decreased its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 68.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,400 shares of the company's stock afApril 29, 2025 | marketbeat.comCastle Biosciences (CSTL) Expected to Announce Quarterly Earnings on MondayCastle Biosciences (NASDAQ:CSTL) will be releasing its Q1 2025 earnings after the market closes on Monday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-5-castle-biosciences-inc-stock/)April 29, 2025 | marketbeat.comDecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous MelanomaApril 28, 2025 | globenewswire.comCastle Biosciences, Inc. (NASDAQ:CSTL) Shares Bought by Birchview Capital LPBirchview Capital LP lifted its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 34.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 78,000 shares of the company's stock after purchasing an additiApril 28, 2025 | marketbeat.com Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address CSTL Media Mentions By Week CSTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CSTL News Sentiment▼1.080.87▲Average Medical News Sentiment CSTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CSTL Articles This Week▼25▲CSTL Articles Average Week Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GeneDx News Ardent Health Partners News Progyny News National HealthCare News PACS Group News Grail News Teladoc Health News Viridian Therapeutics News AdaptHealth News CareDx News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CSTL) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
